(TCMD) Tactile Systems Technology - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 533m USD | Total Return: 80.9% in 12m

Compression Devices, Wearable Vests, Mobile App
Total Rating 75
Safety 86
Buy Signal 0.68
Medical Devices
Industry Rotation: +4.6
Market Cap: 533M
Avg Turnover: 6.27M USD
ATR: 4.69%
Peers RS (IBD): 92.4
Risk 5d forecast
Volatility48.9%
Rel. Tail Risk-18.8%
Reward TTM
Sharpe Ratio1.11
Alpha78.56
Character TTM
Beta-0.200
Beta Downside0.878
Drawdowns 3y
Max DD63.25%
CAGR/Max DD0.16
EPS (Earnings per Share) EPS (Earnings per Share) of TCMD over the last years for every Quarter: "2021-03": -0.07, "2021-06": 0.07, "2021-09": -0.1, "2021-12": -0.38, "2022-03": -0.46, "2022-06": -0.23, "2022-09": -0.11, "2022-12": 0.23, "2023-03": -0.09, "2023-06": 0.049, "2023-09": 0.94, "2023-12": 0.35, "2024-03": -0.08, "2024-06": 0.18, "2024-09": 0.21, "2024-12": 0.397, "2025-03": -0.1254, "2025-06": 0.14, "2025-09": 0.36, "2025-12": 0.46,
EPS CAGR: 172.33%
EPS Trend: 49.8%
Last SUE: 0.17
Qual. Beats: 0
Revenue Revenue of TCMD over the last years for every Quarter: 2021-03: 42.772, 2021-06: 51.06, 2021-09: 52.497, 2021-12: 61.728, 2022-03: 47.978, 2022-06: 59.645, 2022-09: 65.262, 2022-12: 73.9, 2023-03: 58.846, 2023-06: 68.339, 2023-09: 69.586, 2023-12: 77.652, 2024-03: 61.088, 2024-06: 73.218, 2024-09: 73.093, 2024-12: 85.585, 2025-03: 61.268, 2025-06: 78.905, 2025-09: 85.755, 2025-12: 103.594,
Rev. CAGR: 22.78%
Rev. Trend: 74.2%
Last SUE: 2.95
Qual. Beats: 3

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: TCMD Tactile Systems Technology

Tactile Systems Technology Inc. (TCMD) is a medical technology company. It develops and provides medical devices for chronic diseases.

The companys product portfolio includes pneumatic compression devices. These devices treat conditions such as lymphedema and venous insufficiency. This business model relies on insurance reimbursement for medical devices.

TCMD also offers a mobile application, Kylee, to support patient engagement and data tracking. Additionally, it provides AffloVest, a high-frequency chest wall oscillation vest for respiratory conditions. The health care equipment sector is subject to regulatory approval processes.

For more detailed analysis, explore ValueRays comprehensive reports.

Headlines to Watch Out For
  • Flexitouch Plus sales drive revenue growth
  • Reimbursement policies impact device adoption
  • Competition from alternative therapies affects market share
  • Regulatory approvals essential for new product launches
Piotroski VR‑10 (Strict) 8.0
Net Income: 19.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.15 > 0.02 and ΔFCF/TA 1.94 > 1.0
NWC/Revenue: 37.69% < 20% (prev 46.71%; Δ -9.02% < -1%)
CFO/TA 0.16 > 3% & CFO 42.8m > Net Income 19.1m
Net Debt (-67.5m) to EBITDA (38.1m): -1.77 < 3
Current Ratio: 4.03 > 1.5 & < 3
Outstanding Shares: last quarter (23.0m) vs 12m ago -5.85% < -2%
Gross Margin: 75.17% > 18% (prev 0.74%; Δ 7.44k% > 0.5%)
Asset Turnover: 115.2% > 50% (prev 98.34%; Δ 16.90% > 0%)
Interest Coverage Ratio: 30.35 > 6 (EBITDA TTM 38.1m / Interest Expense TTM 1.04m)
Altman Z'' 5.42
A: 0.45 (Total Current Assets 165.2m - Total Current Liabilities 41.0m) / Total Assets 273.9m
B: 0.20 (Retained Earnings 54.9m / Total Assets 273.9m)
C: 0.11 (EBIT TTM 31.5m / Avg Total Assets 285.9m)
D: 1.00 (Book Value of Equity 55.0m / Total Liabilities 55.0m)
Altman-Z'' Score: 5.42 = AAA
Beneish M -3.15
DSRI: 0.87 (Receivables 43.9m/44.9m, Revenue 329.5m/293.0m)
GMI: 0.98 (GM 75.17% / 73.74%)
AQI: 1.00 (AQ_t 0.33 / AQ_t-1 0.33)
SGI: 1.12 (Revenue 329.5m / 293.0m)
TATA: -0.09 (NI 19.1m - CFO 42.8m) / TA 273.9m)
Beneish M-Score: -3.15 (Cap -4..+1) = AA
What is the price of TCMD shares? As of April 14, 2026, the stock is trading at USD 24.24 with a total of 181,403 shares traded.
Over the past week, the price has changed by -1.34%, over one month by -9.99%, over three months by -19.07% and over the past year by +80.90%.
Is TCMD a buy, sell or hold? Tactile Systems Technology has received a consensus analysts rating of 3.40. Therefor, it is recommend to hold TCMD.
  • StrongBuy: 1
  • Buy: 0
  • Hold: 4
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TCMD price?
Analysts Target Price 38 56.8%
Tactile Systems Technology (TCMD) - Fundamental Data Overview as of 14 April 2026
P/E Trailing = 28.5732
P/E Forward = 19.1205
P/S = 1.6176
P/B = 2.4351
P/EG = 17.792
Revenue TTM = 329.5m USD
EBIT TTM = 31.5m USD
EBITDA TTM = 38.1m USD
Long Term Debt = 16.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.19m USD (from shortTermDebt, last quarter)
Debt = 16.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -67.5m USD (from netDebt column, last quarter)
Enterprise Value = 465.6m USD (533.0m + Debt 16.0m - CCE 83.4m)
Interest Coverage Ratio = 30.35 (Ebit TTM 31.5m / Interest Expense TTM 1.04m)
EV/FCF = 11.52x (Enterprise Value 465.6m / FCF TTM 40.4m)
FCF Yield = 8.68% (FCF TTM 40.4m / Enterprise Value 465.6m)
FCF Margin = 12.26% (FCF TTM 40.4m / Revenue TTM 329.5m)
Net Margin = 5.79% (Net Income TTM 19.1m / Revenue TTM 329.5m)
Gross Margin = 75.17% ((Revenue TTM 329.5m - Cost of Revenue TTM 81.8m) / Revenue TTM)
Gross Margin QoQ = 75.84% (prev 75.80%)
Tobins Q-Ratio = 1.70 (Enterprise Value 465.6m / Total Assets 273.9m)
Interest Expense / Debt = 0.07% (Interest Expense 11.0k / Debt 16.0m)
Taxrate = 45.32% (8.81m / 19.4m)
NOPAT = 17.2m (EBIT 31.5m * (1 - 45.32%))
Current Ratio = 4.03 (Total Current Assets 165.2m / Total Current Liabilities 41.0m)
Debt / Equity = 0.07 (Debt 16.0m / totalStockholderEquity, last quarter 218.9m)
Debt / EBITDA = -1.77 (Net Debt -67.5m / EBITDA 38.1m)
Debt / FCF = -1.67 (Net Debt -67.5m / FCF TTM 40.4m)
Total Stockholder Equity = 206.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.67% (Net Income 19.1m / Total Assets 273.9m)
RoE = 9.26% (Net Income TTM 19.1m / Total Stockholder Equity 206.1m)
RoCE = 14.19% (EBIT 31.5m / Capital Employed (Equity 206.1m + L.T.Debt 16.0m))
RoIC = 7.88% (NOPAT 17.2m / Invested Capital 218.6m)
WACC = 5.13% (E(533.0m)/V(549.0m) * Re(5.28%) + D(16.0m)/V(549.0m) * Rd(0.07%) * (1-Tc(0.45)))
Discount Rate = 5.28% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -33.33 | Cagr: -0.81%
[DCF] Terminal Value 88.44% ; FCFF base≈39.5m ; Y1≈48.7m ; Y5≈83.1m
[DCF] Fair Price = 109.0 (EV 2.41b - Net Debt -67.5m = Equity 2.48b / Shares 22.8m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 49.81 | EPS CAGR: 172.3% | SUE: 0.17 | # QB: 0
Revenue Correlation: 74.21 | Revenue CAGR: 22.78% | SUE: 2.95 | # QB: 3
EPS next Quarter (2026-06-30): EPS=0.17 | Chg7d=+0.040 | Chg30d=+0.040 | Revisions Net=+2 | Analysts=2
EPS current Year (2026-12-31): EPS=1.11 | Chg7d=+0.170 | Chg30d=+0.170 | Revisions Net=+2 | Growth EPS=+34.0% | Growth Revenue=+9.4%
EPS next Year (2027-12-31): EPS=1.48 | Chg7d=+0.200 | Chg30d=+0.200 | Revisions Net=+2 | Growth EPS=+32.7% | Growth Revenue=+9.2%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = +4.0% (Analyst 8.4% - Implied 4.4%)
External Resources
Dataroma Stockcircle